Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis

Giovanni Targher

DOI: https://doi.org/10.1111/apt.17747

IF: 9.524

2023-12-14

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 1, Page 128-129, January 2024.

pharmacology & pharmacy,gastroenterology & hepatology

What problem does this paper attempt to address?

Resmetirom: The First Food and Drug Administration–Approved Medication for Nonalcoholic Steatohepatitis (NASH)

Erenie Guirguis,John Dougherty,Krisy Thornby,Yasmin Grace,Keri Mack

DOI: https://doi.org/10.1177/10600280241259528

IF: 3.4628

2024-06-20

Annals of Pharmacotherapy

Abstract:Annals of Pharmacotherapy, Ahead of Print. Objective:To review the literature leading to the Food and Drug Administration (FDA) approval of the first medication, resmetirom, for the treatment of nonalcoholic steatohepatitis (NASH), including the pharmacology, pharmacokinetics, clinical studies, dosing, and adverse effects. Relevant data will be used to discuss how resmetirom impacts clinical practice.Data sources:A literature search was conducted using MEDLINE from database inception to May 12, 2024. Keywords included non-alcoholic steatohepatitis, nonalcoholic fatty liver disease, and resmetirom. Study selection, data extraction and all English-language studies involving the use of resmetirom for nonalcoholic fatty liver disease (NAFLD)/NASH were included.Data synthesis:Resmetirom, a thyroid hormone receptor agonist, is administered at daily doses of either 80 mg or 100 mg. The drug was shown to provide NASH resolution as assessed by the NAFLD activity score, 80 mg-24.2%, 100 mg-25.9% compared to 14.2% with the placebo group (P < 0.001). Resmetirom, improved liver fibrosis, 80 mg-25.9%, 100 mg-29.9% compared to 9.7% with the placebo group (P < 0.001). Resmetirom's ability to improve fibrosis in patients with F2-F3 fibrosis offers valuable benefit for patients at risk of progressing to cirrhosis.Relevance to patient care and clinical practice:Resmetirom expands the medication options available to treat patients with NASH which can be given alongside other medications to optimize metabolic factors such as glucagon-like peptide-1 and hydroxymethylglutaryl-coenzyme A reductase inhibitors. Resmetirom was well tolerated in studies.Conclusion:Resmetirom serves as an attractive option in patients diagnosed with NASH with evidence of advanced fibrosis (F2-F3) in combination with exercise, diet, and other multimodal therapies targeting metabolic risk factors.

pharmacology & pharmacy
Resmetirom's Approval: Highlighting the Need for Comprehensive Approaches in NASH Therapeutics

Salah Abdalrazak Alshehade

DOI: https://doi.org/10.1016/j.clinre.2024.102377

IF: 3.189

2024-05-22

Clinics and Research in Hepatology and Gastroenterology

Abstract:The recent FDA approval of Rezdiffra (resmetirom), an oral partial agonist of the thyroid hormone receptor-beta (THR-beta), for the treatment of noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced fibrosis, has challenged conventional approaches to NASH drug development. Despite extensive efforts targeting typical pathways involved in NASH progression, such as lipogenesis, oxidative stress, and inflammation, these approaches have yet to yield any approved therapies. The success of resmetirom highlights the potential advantages of targeting THR-beta, which exerts pleiotropic effects on multiple pathways involved in NASH pathogenesis, including lipid metabolism, glucose homeostasis, and inflammation. In the phase 3 MAESTRO-NASH trial, resmetirom significantly improved NASH resolution, fibrosis, and LDL cholesterol levels compared to placebo, with a favorable safety profile. The tissue-specific action of resmetirom may also contribute to its efficacy and safety. The approval of resmetirom has opened new avenues for NASH drug development, emphasizing the importance of exploring novel mechanisms of action, developing targeted therapies, and embracing a more comprehensive approach to treatment. As the global burden of NASH continues to grow, the lessons learned from the success of resmetirom should inform future drug development strategies, offering hope to the millions of patients affected by this disease worldwide.

gastroenterology & hepatology
Ann Robinson's research reviews—15 February 2024

Ann Robinson

DOI: https://doi.org/10.1136/bmj.q366

2024-02-16

BMJ

Abstract:Resmetirom for non-alcoholic steatohepatitisThe global incidence of non-alcoholic fatty liver disease is estimated to be one in 20. About a fifth of cases will cause liver cell inflammation and damage known as non-alcoholic steatohepatitis (NASH). As NASH progresses to severe fibrosis and on to cirrhosis, the risk of death from liver disease increases. Lifestyle changes help early stage NASH, but there's no approved drug treatment as yet. This phase 3 trial is encouraging. Among 966 patients with NASH, resmetirom (80 mg and 100 mg doses)—an oral, liver-directed, thyroid hormone receptor agonist that reduces fibrosis—was more effective than placebo in resolution of NASH with no worsening of fibrosis (26% v 30% v 10%) and improving liver fibrosis (24% v 26% v 14%) over one year. Lipid profiles improved too, which is helpful as most of these patients with NASH also had diabetes and are at increased risk of cardiovascular disease. N...

medicine, general & internal
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Stephen A. Harrison,Pierre Bedossa,Cynthia D. Guy,Jörn M. Schattenberg,Rohit Loomba,Rebecca Taub,Dominic Labriola,Sam E. Moussa,Guy W. Neff,Mary E. Rinella,Quentin M. Anstee,Manal F. Abdelmalek,Zobair Younossi,Seth J. Baum,Sven Francque,Michael R. Charlton,Philip N. Newsome,Nicolas Lanthier,Ingolf Schiefke,Alessandra Mangia,Juan M. Pericàs,Rashmee Patil,Arun J. Sanyal,Mazen Noureddin,Meena B. Bansal,Naim Alkhouri,Laurent Castera,Madhavi Rudraraju,Vlad Ratziu

DOI: https://doi.org/10.1056/nejmoa2309000

IF: 158.5

2024-02-08

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 390, Issue 6, Page 497-509, February 2024.

medicine, general & internal
Safety and efficacy of resmetirom in the treatment of patients with non-alcoholic steatohepatitis and liver fibrosis: a systematic review and meta-analysis

Adarsh Raja,Raja Subhash Sagar,Sadia Saeed,Amna Zia Ul Haq,Owais Khan,Parshant Dileep Bhimani,Sandesh Raja,Fnu Deepak,Muhammad Ahmed,Muhammad Ashir Shafique,Muhammad Saqlain Mustafa,Muhammad Sohaib Asghar,Varsha Sharma

DOI: https://doi.org/10.1097/MS9.0000000000002195

2024-05-22

Abstract:Introduction: Non-alcoholic fatty liver disease (NAFLD), spanning from non-alcoholic steatohepatitis (NASH) to liver fibrosis, poses a global health challenge amid rising obesity and metabolic syndrome rates. Effective pharmacological treatments for NASH and liver fibrosis are limited. Objective: This study systematically reviews and meta-analyzes the safety and efficacy of resmetirom, a selective thyroid hormone receptor-β agonist, in NASH and liver fibrosis treatment. By analyzing data from clinical trials, we aim to offer evidence-based recommendations for resmetirom's use in managing these conditions and identify avenues for future research. Methods: Electronic databases (PubMed, Scopus, Science Direct, Google Scholar, ClinicalTrials.gov, and Cochrane CENTRAL) were systematically searched, supplemented by manual screening of relevant sources. Only English-language randomized controlled trials were included. Data extraction, risk of bias assessment, pooled analyses, and meta-regression were performed. Results: Three randomized controlled trials involving 2231 participants were analyzed. Resmetirom demonstrated significant reductions in hepatic fat fraction [standardized mean difference (SMD) -4.61, 95% CI -6.77 to -2.44, P < 0.0001], NASH resolution without worsening fibrosis [risk ratio (RR) 2.51, 95% CI 1.74-3.64, P = 0.00001), and liver fibrosis improvement (RR 2.31, 95% CI 1.20-4.44, P = 0.01). Secondary outcomes showed significant improvements in lipid profiles, liver enzymes, and NASH biomarkers with resmetirom treatment. Meta-regression revealed associations between covariates and primary outcomes. Conclusion: Resmetirom exhibits promising efficacy in reducing hepatic fat, improving NASH resolution, and ameliorating liver fibrosis with a favorable safety profile. Further research is warranted to validate findings and optimize therapeutic strategies for NASH and liver fibrosis management.
Resmetirom: A Systematic Review of the Revolutionizing Approach to Non-alcoholic Steatohepatitis Treatment Focusing on Efficacy, Safety, Cost-Effectiveness, and Impact on Quality of Life

Parikshit Bittla,Sai Pavitra Paidimarri,Shriya Ayuthu,Yashkumar D Chauhan,Moyal Z Saad,Amna A Mirza,Safeera Khan

DOI: https://doi.org/10.7759/cureus.69919

2024-09-22

Cureus

Abstract:There has been a rise in the prevalence of non-alcoholic steatohepatitis (NASH), a subset of non-alcoholic fatty liver disease (NAFLD) with an ongoing increase in the prevalence of linked conditions such as obesity, type II diabetes mellitus, and metabolic syndrome. To date, there are no specific drugs that are approved for the treatment of NAFLD/NASH. With the recent discovery of association between subclinical hypothyroidism and NASH, various trials exploring treatment options for NASH using thyroid hormone derivatives led to the discovery of resmetirom (MGL-316) with high affinity to thyroid hormone receptors (THRs) targeting the liver. Following standardized guidelines, a systematic review was performed on the safety, efficacy, and other practical aspects of resmetirom in the treatment of NASH. Advanced search was carried out using the MeSH search strategy and appropriate keywords in major databases using various inclusion and exclusion criteria. The search was narrowed down to seven high-quality articles: four randomized control trials (RCTs), and three reviews to be included in the current study. The online database search yielded 62 articles, out of which six high-quality articles were selected to be included in the current systematic review after deleting duplicates and screening for irrelevant titles, and articles. Out of the three RCTs, two of them assessed the safety and efficacy of resmetirom, while the remaining RCT assessed the impact on health-related quality of life with resmetirom on patients with NASH. resmetirom (MGL-316) is a thyroid hormone derivative with high affinity to THRs targeting the liver and acts by improving mitochondrial oxidation, and lipophagy in the hepatic cell line. All the trials suggested in favor of resmetirom with a decrease in NASH fibrosis score by at least two points, along with reduction in hepatic fat content (minimum relative reduction of 20%), liver volume by 61%, improving secondary outcomes such as low-density lipoprotein-C, apolipoprotein-B, triglycerides, and hepatic enzymes with greater reduction in the study groups treated with higher doses of resmetirom with no significant increase in adverse events. Resmetirom was found to improve patient-reported outcomes, and thereby quality-adjusted life years (QALYs) in 12 weeks while being cost-effective compared to placebo at a willingness-to-pay threshold of US$100,000 up to a daily threshold of US$72.00, and an effective incremental cost-effectiveness ratio of US$53,925 per QALY gained. After carefully analyzing the available data by our team members, it could be concluded that resmetirom holds a strong potential to be implemented as a drug of choice in treating NAFLD/NASH in the coming years with proven efficacy, safety while being cost-effective, and also reducing secondary co-morbidities by improving cardiovascular risk factors. The results can be best achieved when combined with conventional approaches such as weight loss and dietary modifications. Long-term safety and sustainability of the achieved results are yet to be confirmed with large-scale clinical trials. However, resmetirom is still an investigational drug and could be expected to be available for clinical practice in the near future.
Resmetirom proves positive for NASH with liver fibrosis

Katrina Ray

DOI: https://doi.org/10.1038/s41575-024-00909-0

2024-02-16

Nature Reviews Gastroenterology & Hepatology

Abstract:Positive phase III results have been reported for resmetirom (a thyroid hormone receptor β-selective agonist) for the treatment of nonalcoholic steatohepatitis (NASH; also known as metabolic dysfunction-associated steatohepatitis (MASH)) with liver fibrosis. In a phase III, randomized controlled trial, 966 patients with biopsy-confirmed NASH and liver fibrosis (stage F1B, F2 or F3) were randomly assigned to receive a once-daily dose of 80 mg resmetirom, 100 mg resmetirom or placebo for 52 weeks. Resolution of NASH with no worsening of fibrosis was achieved in 25.9% of the 80 mg group and 29.9% of the 100 mg group, compared with 9.7% in the placebo group ( P < 0.001 for both comparisons). Improvement in fibrosis by at least one stage with no worsening of disease activity scores occurred in 24.2% of the 80 mg group and 25.9% of patients in the 100 mg group, versus 14.2% in the placebo group ( P < 0.001 for both comparisons). Moreover, LDL cholesterol levels were also reduced by resmetirom (from baseline to week 24, –13.6% in the 80 mg group, –16.3% in the 100 mg group, 0.1% in the placebo group; P < 0.001).

gastroenterology & hepatology
Unveiling Resmetirom: A systematic review and meta-analysis on its impact on liver function and safety in non-alcoholic steatohepatitis treatment

Hashim Talib Hashim,Ahmed Qasim Mohammed Alhatemi,Sania Riaz,Mohammedbaqer Ali Al-Ghuraibawi,Arwa S Alabide,Humza Saeed,Fatimah Abdullah Sulaiman,Mustafa Ali Abd Alhussain,Maythum Ali Shallan,Ahmed Dheyaa Al-Obaidi,Omar Saab,Hasan Al-Obaidi,Ali Talib Hashim,Nooraldin Merza

DOI: https://doi.org/10.1002/jgh3.70025

2024-10-01

JGH Open

Abstract:Background and aim: The role of Resmetirom in non-alcoholic steatohepatitis (NASH) represents a promising therapeutic approach in addressing the growing global burden of liver disease. With NASH emerging as a leading cause of liver-related morbidity and mortality worldwide, there is an urgent need for effective treatments. Resmetirom, a selective thyroid hormone receptor-β agonist, offers potential benefits in improving liver histology and metabolic parameters in patients with NASH. This review examines the current evidence surrounding Resmetirom's role in NASH management. Methods: A systematic review and meta-analysis was done by searching in Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, MEDLINE (including MEDLINE InProcess) (OvidSP), Web of Science, Embase (OvidSP), and Scopus databases. ROB2 Cochrane tool was used for assessing risk of bias in randomized controlled trials (RCTs). In the analysis, we used RevMan Cochrane software. Results: The study showed that patients who were treated with Resmetirom had significantly lower low-density lipoprotein-cholesterol (LDL-C) levels (mean difference [MD] -10.45; 95% confidence interval [CI] -15.86 to -5.83; P < 0.001) and alanine aminotransferase (ALT) levels (MD -7.18; 95% CI -12.67 to -1.68; P = 0.01) as compared with those in the placebo group. The risk of adverse events including diarrhea [risk ratio (RR) 1.81; 95% CI 1.40 to 2.35; P < 0.001] and nausea (RR 1.72; 95% CI 1.31 to 2.27; P < 0.001) was significantly increased for the Resmetirom group as compared with the placebo group. Conclusion: Resmetirom presents a promising therapeutic option for NASH, offering potential benefits in reducing liver fat content and improving histological outcomes. The encouraging results from clinical trials suggest that Resmetirom may address an unmet need in NASH management, providing hope for patients with this progressive liver disease. Further research and long-term studies are warranted to validate its efficacy and safety profile in larger patient populations.
The first MASH drug therapy on the horizon: Current perspectives of resmetirom

Salvatore Petta,Giovanni Targher,Stefano Romeo,Utpal B. Pajvani,Ming‐Hua Zheng,Alessio Aghemo,Luca V. C. Valenti

DOI: https://doi.org/10.1111/liv.15930

IF: 8.754

2024-04-06

Liver International

Abstract:The rising prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) poses a significant global health challenge, affecting over 30% of adults worldwide. MASLD is linked to increased mortality rates and substantial healthcare costs, primarily driven by its progression to metabolic dysfunction‐associated steatohepatitis (MASH), which can lead to severe liver complications including cirrhosis and hepatocellular carcinoma. Despite its growing burden, effective pharmacotherapy for MASLD/MASH has been lacking until the recent conditional approval of resmetirom by the FDA. Resmetirom, a liver‐targeted thyroid hormone receptor‐β selective drug, has shown promise in clinical trials for treating non‐cirrhotic MASH with moderate to advanced fibrosis. It has demonstrated efficacy in reducing hepatic fat content, improving liver histology (both MASH resolution and fibrosis improvement), and ameliorating biomarkers of liver damage without significant effects on body weight or glucose metabolism. Notably, resmetirom also exhibits favourable effects on circulating lipids, potentially reducing cardiovascular risk in MASLD/MASH patients. The safety profile of resmetirom appears acceptable, with gastrointestinal adverse events being the most common, though generally mild or moderate. However, long‐term surveillance is warranted to monitor for potential risks related to thyroid, gonadal, or bone diseases. Clinical implementation of resmetirom faces challenges in patient selection and monitoring treatment response, and will heavily rely on non‐invasive tests for liver fibrosis assessment. Nonetheless, resmetirom represents a landmark breakthrough in MASLD/MASH treatment, paving the way for future therapeutic strategies aiming to mitigate the multifaceted risks associated with this complex metabolic liver disease.

gastroenterology & hepatology
Resmetirom for treatment of MASH

Silvia Sookoian,Carlos Jose Pirola

DOI: https://doi.org/10.1016/j.cell.2024.05.009

IF: 64.5

2024-06-07

Cell

Abstract:Resmetirom is an oral selective THR-β agonist conditionally approved for the treatment of patients with noncirrhotic MASH with moderate to advanced fibrosis. Resmetirom restores mitochondrial and hepatic metabolic function; reduces atherogenic lipids; improves hepatic steatosis, inflammation, and fibrosis; and has no significant effect on THR-α. To view this Bench to Bedside, open or download the PDF.

biochemistry & molecular biology,cell biology
Efficacy and safety of resmetirom among patients with non-alcoholic steatohepatitis: a systematic review and meta-analysis

Saad Mazhar,Aima Azhar,Ariba Khan,Gulrukh Shakil,Sapna Kumari,Deepa Devi,Sayed Jawad

DOI: https://doi.org/10.1097/MS9.0000000000002314

2024-07-15

Abstract:Background: Non-alcoholic steatohepatitis (NASH) is a severe medical illness that has few available therapeutic options. Resmetirom, a liver-targeting agonist of the thyroid hormone receptor (THR), has recently been licenced by the FDA. We assess the effectiveness and safety of resmetirom in patients with NASH. Methods: PubMed, SCOPUS and Cochrane Central were searched till March 2024 to find potential articles. Outcomes assessed included MRI-proton density fat fraction (MRI-PDFF), Fat Reduction, and NASH Resolution Without Fibrosis, changes in aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), low-density lipoprotein (LDL), and triglyceride (TG) levels, along with diarrhoea, nausea, urinary tract infection (UTI), and headache. Subgroup analysis was performed between outcomes before and after 6 months. Outcomes were analyzed with a random-effects model and results presented as mean difference (MD) for continuous outcomes and odds ratios (OR) for safety analysis, along with their 95% confidence intervals. A risk of bias assessment was performed using Cochrane Risk of Bias tool. Results: Four randomized controlled trials (RCTs) were included in our analysis. Resmetirom shown a substantial improvement in MRI-PDFF with a MD of -19.23 (P<0.00001). Additionally, it resulted in a 30% reduction in fat (OR: 3.54, P=0.004) and resolution of NASH without fibrosis (OR: 2.41, P=0.04). There was no notable enhancement observed in AST levels, with a mean difference of -0.87 and a P value of 0.73. The usage of resmetirom resulted in significant improvement in ALT levels (MD: -4.36, P value: 0.32), GGT levels (MD: -17.87, P value: <0.00001), TG levels (MD: -23.48, P value: <0.00001), LDL levels (mean difference: -12.80, P value: <0.00001), and rT3 levels (MD: -2.08, P value: <0.00001). The use of Resmetirom was associated with a higher likelihood of experiencing diarrhoea (OR: 2.07, P<0.0001) and nausea (OR: 1.81, P=0.0003). However, there was no significant difference observed in the occurrence of UTI (OR: 1.04, P=0.85) or headaches (OR: 0.79, P=0.48). Conclusion: Resmetirom demonstrates efficacy in enhancing MRI-PDFF score, diminishing adipose tissue, resolving NASH without fibrosis, reducing GGT, TG, LDL, reverse triiodothyronine (rT3) levels in NASH patients. Nevertheless, there is also an observed heightened susceptibility to experiencing diarrhoea and nausea. Additional trials are necessary to further examine the efficacy and safety of this medication.
Relationship of non-invasive measures with histological response in patients with nonalcoholic steatohepatitis and fibrosis: 52-week data from the Phase 3 MAESTRO-NASH trial

A. Mangia,R. Loomba,JM. Schattenberg,R. Taub,D. Labriola,M. Noureddin,V. Ratziu,S.A. Harrison

DOI: https://doi.org/10.1016/j.dld.2024.01.022

IF: 5.165

2024-02-01

Digestive and Liver Disease

Abstract:Introduction MAESTRO-NASH (NCT03900429) is an ongoing 54-month, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis. 966 patients were randomized 1:1:1 to resmetirom 80mg, 100mg, or placebo administered once daily. Histologic endpoints were assessed after 52 weeks. Dual primary endpoints were achieved with both resmetirom 80mg and 100mg: NASH resolution with no worsening of fibrosis (NR) or ≥1-stage reduction in fibrosis with no worsening of NAS (FR). Adults with ≥3 metabolic risk factors, liver stiffness ≥8.5 kPa, hepatic fat ≥8%, biopsy-confirmed NASH with F1B-F3 fibrosis, and NAS ≥4 were eligible to participate in MAESTRO-NASH. Aim To assess the relationship of non-invasive measures with histological response (NR and/or FR) in the resmetirom 80mg, resmetirom 100mg, and placebo groups. Results Patients with biopsy-confirmed NASH with fibrosis had high metabolic risk. Among patients treated with resmetirom 80mg or 100mg who achieved a ≥30% reduction from baseline in MRI-PDFF, NR was observed in 28% and 38% and FR in 17% and 18% more patients than placebo. A ≥30% PDFF response was observed in 96%, 88%, and 92% of resmetirom 100mg NR, FR, and NR and/or FR responders. Half of resmetirom ≥30% PDFF responders without NR or FR showed ≥2-point NAS reduction. On biopsy, NR correlated (r2) with FR (=0.30). Additional correlates (r2) of NR and FR at resmetirom 100mg included reduction in PDFF (0.39, 0.23); ALT (0.20, 0.24); and liver volume (0.25, 0.18). Conclusions Achievement of NASH resolution and fibrosis reduction was associated with a ≥30% reduction from baseline in MRI-PDFF - at both resmetirom doses (80 and 100mg). Additional analyses are ongoing.

gastroenterology & hepatology
Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner

Xiaojing Wang,Liangjing Wang,Lin Geng,Naoki Tanaka,Bin Ye

DOI: https://doi.org/10.3390/ijms24065843

IF: 5.6

2023-03-20

International Journal of Molecular Sciences

Abstract:Resmetirom, a liver-directed, orally active agonist of THR-β, could play a favorable role in treating NASH, but little is known about the underlying mechanism. A NASH cell model was established to test the preventive effect of resmetirom on this disease in vitro. RNA-seq was used for screening, and rescue experiments were performed to validate the target gene of the drug. A NASH mouse model was used to further elucidate the role and the underlying mechanism of resmetirom. Resmetirom effectively eliminated lipid accumulation and decreased triglyceride (TG) levels. In addition, repressed RGS5 in the NASH model could be recovered by resmetirom treatment. The silencing of RGS5 effectively impaired the role of resmetirom. In the NASH mouse model, obvious gray hepatization, liver fibrosis and inflammation, and increased macrophage infiltration were observed in liver tissues, while resmetirom almost returned them to normal conditions as observed in the control group. Pathological experimental data also confirmed that resmetirom has great potential in NASH treatment. Finally, RGS5 expression was suppressed in the NASH mouse model, but it was upregulated by resmetirom treatment, while the STAT3 and NF-κB signaling pathways were activated in NASH but inhibited by the agent. Resmetirom could improve NASH by recovering RGS5 expression and subsequently inactivating the STAT3 and NF-κB signaling pathways.

biochemistry & molecular biology,chemistry, multidisciplinary
Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis

Zobair M Younossi,Maria Stepanova,Andrei Racila,Linda Henry,Dominic Labriola,Rebecca Taub,Fatema Nader

DOI: https://doi.org/10.1097/HEP.0000000000001084

IF: 17.298

2024-09-06

Hepatology

Abstract:Background/aims: Resmetirom, liver directed thyroid-hormone receptor-β agonist, received approval for MASH treatment. We assessed HRQL in MASH patients treated with resmetirom. Methods: Non-cirrhotic MASH/NASH patients with confirmed/suspected fibrosis were enrolled in a 54-month double-blind randomized placebo-controlled Phase 3 clinical trial with serial biopsy assessments (MAESTRO-NASH, NCT03900429) at baseline and Week 52. HRQL was assessed using Chronic Liver Disease Questionnaire-NASH (CLDQ-NAFLD) and Liver Disease Quality of Life (LDQOL). Baseline HRQL score changes by treatment group (resmetirom 80 mg, resmetirom 100 mg or placebo) and histological response (improvement of fibrosis without worsening of NAS or resolution of MASH/NASH without worsening of fibrosis) were compared after 52 weeks. Results: Included were 966 ITT patients: 323 received resmetirom 100 mg, 322 resmetirom 80 mg, 321 placebo. By weeks 24 and 52, patients receiving 80 or 100 mg resmetirom experienced HRQL improvement CLDQ-NAFLD worry domain (mean +0.21 to +0.24, p<0.05). At week 52, subjects who met histologic endpoints after treatment with resmetirom (100 mg and 80 mg pooled) experienced HRQL improvement in CLDQ-NAFLD Worry +0.46 (41% met MCID), LDQOL domains: Role Emotional +3.0 (28% met MCID), Health Distress +8.1 (38% MCID), Stigma +3.5 (39% MCID) and total LDQOL +2.2 (35% MCID) (all p<0.05). Similar improvements noted in histologic responders from 100 mg or 80 mg resmetirom groups when separated- no improvements in placebo or nonresponders. Baseline F3 histologic responders had similar/more pronounced HRQL improvements. Conclusions: MASH/NASH patients with fibrosis improvement or resolution of MASH with resmetirom experienced clinically meaningful and statistically significant HRQL improvements.
Resmetirom: First Approval

Susan J. Keam

DOI: https://doi.org/10.1007/s40265-024-02045-0

2024-05-22

Drugs

Abstract:Resmetirom (RezdiffraTM) is an oral thyroid hormone receptor-β (THR-β) agonist being developed by Madrigal Pharmaceuticals, Inc., to target the key underlying causes of metabolic dysfunction associated steatohepatitis (MASH) [previously known as nonalcoholic steatohepatitis (NASH)]. In March 2024, resmetirom was approved for use (under accelerated approval) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in the USA. Resmetirom is also under regulatory review in the EU for the treatment of MASH/NASH. This article summarizes the milestones in the development of resmetirom leading to this first approval for the treatment of adults with MASH/NASH.

pharmacology & pharmacy,toxicology
Beyond resmetirom approval for NAFLD: what has to be done?

Devaraj Ezhilarasan

DOI: https://doi.org/10.1016/j.drudis.2024.104185

IF: 8.369

2024-09-22

Drug Discovery Today

Abstract:Drug Discov Today . 2024 Sep 18:104185. doi: 10.1016/j.drudis.2024.104185. Online ahead of print. NO

pharmacology & pharmacy
Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis

Stergios A Polyzos,Eun Seok Kang,Chrysoula Boutari,Eun-Jung Rhee,Christos S Mantzoros

DOI: https://doi.org/10.1016/j.metabol.2020.154203

IF: 13.934

Metabolism

Abstract:Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease and important unmet medical need. Current guidelines recommend, under specific restrictions, pioglitazone or vitamin E in patients with NASH and significant fibrosis, but the use of both remains off-label. We summarize evidence on medications for the treatment of nonalcoholic steatohepatitis (NASH), since NASH has been mainly associated with higher morbidity and mortality. Some of these medications are currently in phase 3 clinical trials, including obeticholic acid (a farnesoid X receptor agonist), elafibranor (a peroxisome proliferator activated receptor [PPAR]-α/δ dual agonist), cenicriviroc (a CC chemokine receptor antagonist), MSDC-0602 K (a PPAR sparing modulator), selonsertib (an apoptosis signal-regulating kinase-1 inhibitor) and resmetirom (a thyroid hormone receptor agonist). A significant research effort is also targeting PPARs and selective PPAR modulators, including INT131 and pemafibrate, with the expectation that novel drugs may have beneficial effects similar to those of pioglitazone, but without the associated adverse effects. Whether these and other medications could offer tangible therapeutic benefits, alone or in combination, apparently on a background of lifestyle modification, i.e. exercise and a healthy dietary pattern (e.g. Mediterranean diet) remain to be proven. In conclusion, major advances are expected for the treatment of NASH.
S1981 A Systematic Review Comparing GLP-Agonists and Resmetirom for Improving Fibrosis among Patients With Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Mahmoud Mahdi,Hasan Jaber,Nader Al Souky,William J. Salyers,Nathan Tofteland,Robert Badgett

DOI: https://doi.org/10.14309/01.ajg.0001037292.83414.fb

2024-10-26

The American Journal of Gastroenterology

Abstract:Metabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent condition characterized by excessive fat accumulation in the liver, ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). With the rising global incidence of obesity and metabolic syndrome, MAFLD has emerged as a leading cause of chronic liver disease affecting a quarter of Americans. In March 2024, FDA approved the first drug to treat NASH. Prior to that date, other drugs, including GLP-1 agonists were used. In this study, we compare the use of GLP-1 agonist with resmetirom in reversing fibrosis.

gastroenterology & hepatology
Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis

Bercaw, Eric M.

DOI: https://doi.org/10.1007/s12325-024-02989-5

2024-09-19

Advances in Therapy

Abstract:As of March 2024, resmetirom is the first and only therapy approved in the United States (US) for the treatment of adults with non-cirrhotic nonalcoholic steatohepatitis (NASH) with moderate-to-advanced liver fibrosis (MALF) consistent with stages F2/F3 fibrosis. Estimates of the diagnosed, treatment-eligible NASH population are poorly understood due to diagnostic variability. This study provides a contemporary estimate of the size of the US resmetirom treatment-eligible population.

pharmacology & pharmacy,medicine, research & experimental

Editorial: Resmetirom – a promising treatment option for NASH and liver fibrosis

Resmetirom: The First Food and Drug Administration–Approved Medication for Nonalcoholic Steatohepatitis (NASH)

Resmetirom's Approval: Highlighting the Need for Comprehensive Approaches in NASH Therapeutics

Ann Robinson's research reviews—15 February 2024

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Safety and efficacy of resmetirom in the treatment of patients with non-alcoholic steatohepatitis and liver fibrosis: a systematic review and meta-analysis

Resmetirom: A Systematic Review of the Revolutionizing Approach to Non-alcoholic Steatohepatitis Treatment Focusing on Efficacy, Safety, Cost-Effectiveness, and Impact on Quality of Life

Resmetirom proves positive for NASH with liver fibrosis

Unveiling Resmetirom: A systematic review and meta-analysis on its impact on liver function and safety in non-alcoholic steatohepatitis treatment

The first MASH drug therapy on the horizon: Current perspectives of resmetirom

Resmetirom for treatment of MASH

Efficacy and safety of resmetirom among patients with non-alcoholic steatohepatitis: a systematic review and meta-analysis

Relationship of non-invasive measures with histological response in patients with nonalcoholic steatohepatitis and fibrosis: 52-week data from the Phase 3 MAESTRO-NASH trial

Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner

Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis

Resmetirom: First Approval

Beyond resmetirom approval for NAFLD: what has to be done?

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis

S1981 A Systematic Review Comparing GLP-Agonists and Resmetirom for Improving Fibrosis among Patients With Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis